Keyphrases
Dipeptidyl peptidase-4 (DPP-4)
100%
Randomized Controlled Trial
100%
Hypoglycemia Risk
12%
Heart Failure Hospitalization
12%
Raising Awareness
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Adverse Events
12%
Hypoglycemia
12%
Chronic Kidney Disease
12%
Glycemic Control
12%
Renal Impairment
12%
Cardiovascular Safety
12%
Hyperglycemia
12%
Non-associated
12%
Type 2 Diabetes Mellitus Patients
12%
Phase III Clinical Trial
12%
General Practice
12%
Cardiovascular Outcome Trials
12%
In-hospital Management
12%
High-risk Individuals
12%
Established Cardiovascular Disease
12%
Outcome Trials
12%
Dipeptidyl peptidase-4 Inhibition
12%
Insulin
12%
Metabolic Disorders
12%
Cardiovascular Risk
12%
Safety Outcomes
12%
Medicine and Dentistry
Randomized Controlled Trial
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Hypoglycemia
25%
Maturity Onset Diabetes of the Young
25%
Cardiovascular System
25%
Clinical Study
12%
Cardiovascular Disease
12%
General Medicine
12%
Dipeptidyl Peptidase IV
12%
Hyperglycemia
12%
Adverse Event
12%
Congestive Heart Failure
12%
Clinical Trial
12%
Nephropathy
12%
Glycemic Control
12%
Chronic Kidney Disease
12%
Cardiovascular Risk
12%
Hospital Management
12%
Metabolic Disorder
12%
Awareness
12%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Dipeptidyl Peptidase IV Inhibitor
100%
Hypoglycemia
25%
Non Insulin Dependent Diabetes Mellitus
25%
Clinical Study
12%
Chronic Kidney Failure
12%
Cardiovascular Risk
12%
Cardiovascular Disease
12%
Adverse Event
12%
Kidney Disease
12%
Clinical Trial
12%
Hyperglycemia
12%
Dipeptidyl Peptidase IV
12%
Congestive Heart Failure
12%